{'52WeekChange': 0.17355669,
 'SandP52WeekChange': None,
 'address1': 'South County Business Park',
 'address2': 'Leopardstown',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 185.01,
 'askSize': 1100,
 'averageDailyVolume10Day': 264500,
 'averageVolume': 250144,
 'averageVolume10days': 264500,
 'beta': 0.859383,
 'beta3Year': None,
 'bid': 184.97,
 'bidSize': 1200,
 'bookValue': 28.83,
 'category': None,
 'circulatingSupply': None,
 'city': 'Dublin',
 'companyOfficers': [],
 'country': 'Ireland',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 188.97,
 'dayLow': 182.155,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': -0.48,
 'enterpriseToEbitda': 20.592,
 'enterpriseToRevenue': 3.494,
 'enterpriseValue': 9682514944,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '353 1 247 6260',
 'fiftyDayAverage': 170.24228,
 'fiftyTwoWeekHigh': 199.83,
 'fiftyTwoWeekLow': 104.28,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 51852917,
 'forwardEps': 7.52,
 'forwardPE': 24.609043,
 'fromCurrency': None,
 'fullTimeEmployees': 15150,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.013990001,
 'heldPercentInstitutions': 0.97207,
 'industry': 'Diagnostics & Research',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1218585600,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/iconplc.com',
 'longBusinessSummary': 'ICON Public Limited Company, a clinical research '
                        'organization, provides outsourced development '
                        'services to the pharmaceutical, biotechnology, and '
                        'medical device industries in Ireland, rest of Europe, '
                        'the United States, and internationally. It '
                        'specializes in the strategic development, management, '
                        'and analysis of programs that support various stages '
                        'of the clinical development process from compound '
                        'selection to Phase I-IV clinical studies. The '
                        "company's clinical development services include "
                        'product development planning, strategic consulting, '
                        'study protocol preparation, clinical pharmacology, '
                        'pharmacokinetic and pharmacodynamic analysis, site '
                        'feasibility, patient recruitment and retention, '
                        'digital patient and site, project management, '
                        'clinical operations/monitoring, patient centric '
                        'monitoring, data management, and adaptive and virtual '
                        'trial services. Its clinical development services '
                        'also comprise medical imaging, biostatistics, medical '
                        'affairs, pharmacovigilance, strategic regulatory, '
                        'electronic endpoint adjudication, medical writing and '
                        'publishing, interactive response technologies, '
                        'functional, strategic resourcing central laboratory, '
                        'bioanalytical laboratory, biomarket development, '
                        'strategy and analytics, late phase research, patient '
                        'centered science, and medical device and diagnostics '
                        'research services, as well as access, '
                        'commercialization, and communication services, and '
                        'research trials for us government agencies. The '
                        'company was founded in 1990 and is headquartered in '
                        'Dublin, Ireland.',
 'longName': 'ICON Public Limited Company',
 'market': 'us_market',
 'marketCap': 9717278720,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_397809',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1593475200,
 'navPrice': None,
 'netIncomeToCommon': 328240000,
 'nextFiscalYearEnd': 1640908800,
 'open': 188.97,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 4.7,
 'phone': '353 1 291 2000',
 'previousClose': 189.06,
 'priceHint': 2,
 'priceToBook': 6.419008,
 'priceToSalesTrailing12Months': 3.5065491,
 'profitMargins': 0.12027001,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 188.97,
 'regularMarketDayLow': 182.155,
 'regularMarketOpen': 188.97,
 'regularMarketPreviousClose': 189.06,
 'regularMarketPrice': 188.97,
 'regularMarketVolume': 267645,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 52508800,
 'sharesPercentSharesOut': 0.0113,
 'sharesShort': 592066,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 648424,
 'shortName': 'ICON plc',
 'shortPercentOfFloat': 0.0114,
 'shortRatio': 2.56,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ICLR',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 6.083,
 'trailingPE': 30.422487,
 'twoHundredDayAverage': 161.12094,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'b2bb319f-0763-3a31-bb0d-c06ea5b90dbf',
 'volume': 267645,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.iconplc.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '18'}